Description: Aimovig (erenumab) is a prescription medication used for the prevention of migraines in adults. Aimovig is a monoclonal antibody that works by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule involved in migraine attacks. By inhibiting CGRP, Aimovig helps reduce the frequency and severity of migraine episodes.

Active Ingredient: The active ingredient in Aimovig is erenumab. Erenumab targets and binds to the CGRP receptor, preventing CGRP from attaching to its receptor, thereby reducing migraine-related activity.

Indications: Aimovig is indicated for the preventive treatment of migraines in adults. It is used to reduce the frequency of migraine attacks, helping improve the quality of life for individuals suffering from chronic or episodic migraines.

Usage: Aimovig is administered as a subcutaneous injection, typically once a month. The injection can be self-administered by the patient or given by a healthcare professional. The recommended dosage and administration schedule should be followed as prescribed by a healthcare provider.

Regulatory Approvals: Aimovig has been approved by several major health authorities worldwide, including:

• European Medical Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
• Pharmaceuticals and Medical Devices Agency (PMDA)
• Therapeutic Goods Administration (TGA)
• Swissmedic (CH)
• Medsafe (NZ)

Precautions and Warnings:

• Aimovig should only be used under the supervision of a qualified healthcare provider.
• Patients should inform their healthcare provider about all medical conditions and any other medications they are taking before starting Aimovig.
• Common side effects of Aimovig may include injection site reactions, constipation, and muscle spasms.
• Serious allergic reactions to Aimovig are rare but possible. Patients should seek immediate medical attention if they experience symptoms such as swelling of the face, lips, tongue, or throat, or difficulty breathing.

Storage: Aimovig should be stored in a refrigerator (2°C to 8°C / 36°F to 46°F) in its original carton to protect it from light. Do not freeze or shake the medication. Aimovig can be kept at room temperature (up to 25°C / 77°F) for up to 14 days, but once removed from the refrigerator, it should not be returned. Keep out of reach of children and pets.

Disclaimer: The information provided above is for informational purposes only and should not be considered as medical advice. Patients should consult their healthcare provider for personalized guidance regarding the use of Aimovig or any other medication.